Cancer Research SABCS  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 69, 2655, March 15, 2009. Published Online First March 3, 2009;
doi: 10.1158/0008-5472.CAN-08-2657
© 2009 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
0008-5472.CAN-08-2657v1
69/6/2655    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chisholm, E. J.
Right arrow Articles by Baril, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chisholm, E. J.
Right arrow Articles by Baril, P.

Systems Biology and Emerging Technologies

Cancer-Specific Transgene Expression Mediated by Systemic Injection of Nanoparticles

Edward J. Chisholm1,2, Georges Vassaux9,10, Pilar Martin-Duque6, Raphael Chevre7,8, Olivier Lambert11, Bruno Pitard7,8, Andrew Merron1, Mark Weeks3, Jerome Burnet1, Inge Peerlinck1, Ming-Shen Dai9,10, Ghassan Alusi2, Stephen J. Mather4, Katherine Bolton5, Ijeoma F. Uchegbu5, Andreas G. Schatzlein5 and Patrick Baril9,10

1 Centre for Molecular Oncology, Queen Mary's School of Medicine and Dentistry; 2 Department ENT, Barts and The London NHS Trust; 3 Cancer Proteomics Laboratory, EGA Institute for Women's Health, University College London; 4 Cancer Research United Kingdom, Nuclear Medicine Group, St. Bartholomew's Hospital; 5 The School of Pharmacy, University of London, London, United Kingdom; 6 Centro de Investigación Biomédica de Aragón/Instituto Aragonés de Ciencias de la Salud, Instituto Aragonés de Ciencias de la Salud, Zaragoza, Spain; 7 Institut National de la Santé et de la Recherche Médicale (INSERM) U915; 8 Institut du Thorax, Université de Nantes; 9 INSERM U948, Université de Nantes, CHU Hôtel Dieu; 10 Institut des Maladies de l'Appareil Digestif, CHU Hôtel Dieu, Nantes, France; and 11 CBMN, UMR-CNRS 5248, Université Bordeaux, ENITAB, IECB, Talence, France

Requests for reprints: Georges Vassaux, Institut National de la Santé et de la Recherche Médicale U948, Laboratoire de Biothérapie, 4ème étage HNB Nord, CHU Hotel Dieu, 1 place Alexis Ricordeau, 44035 Nantes Cedex 1, France. Phone: 33-240-08-74-88; Fax: 33-240-08-75-06; E-mail: georges.vassaux{at}nantes.inserm.fr.

Key Words: Synthetic vector • gene transfer • molecular imaging • hNIS • colloidal stability of nanoparticles

The lack of safe and efficient systemic gene delivery vectors has largely reduced the potential of gene therapy in the clinic. Previously, we have reported that polypropylenimine dendrimer PPIG3/DNA nanoparticles are capable of tumor transfection upon systemic administration in tumor-bearing mice. To be safely applicable in the clinic, it is crucial to investigate the colloidal stability of nanoparticles and to monitor the exact biodistribution of gene transfer in the whole body of the live subject. Our biophysical characterization shows that dendrimers, when complexed with DNA, are capable of forming spontaneously in solution a supramolecular assembly that possesses all the features required to diffuse in experimental tumors through the enhanced permeability and retention effect. We show that these nanoparticles are of sizes ranging from 33 to 286 nm depending on the DNA concentration, with a colloidal stable and well-organized fingerprint-like structure in which DNA molecules are condensed with an even periodicity of 2.8 nm. Whole-body nuclear imaging using small-animal nano-single-photon emission computed tomography/computer tomography scanner and the human Na/I symporter (NIS) as reporter gene shows unique and highly specific tumor targeting with no detection of gene transfer in any of the other tissues of tumor-bearing mice. Tumor-selective transgene expression was confirmed by quantitative reverse transcription-PCR at autopsy of scanned animals, whereas genomic PCR showed that the tumor sites are the predominant sites of nanoparticle accumulation. Considering that NIS imaging of transgene expression has been recently validated in humans, our data highlight the potential of these nanoparticles as a new formulation for cancer gene therapy. [Cancer Res 2009;69(6):2655–62]




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
I. Peerlinck, A. Merron, P. Baril, S. Conchon, P. Martin-Duque, C. Hindorf, J. Burnet, M. Quintanilla, M. Hingorani, R. Iggo, et al.
Targeted Radionuclide Therapy Using a Wnt-Targeted Replicating Adenovirus Encoding the Na/I Symporter
Clin. Cancer Res., November 1, 2009; 15(21): 6595 - 6601.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Klutz, V. Russ, M. J. Willhauck, N. Wunderlich, C. Zach, F. J. Gildehaus, B. Goke, E. Wagner, M. Ogris, and C. Spitzweg
Targeted Radioiodine Therapy of Neuroblastoma Tumors following Systemic Nonviral Delivery of the Sodium Iodide Symporter Gene
Clin. Cancer Res., October 1, 2009; 15(19): 6079 - 6086.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.